Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial

BACKGROUND: Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC, 15.4 vs. 4.07 months). We conducted an economic evaluation of pralatrex...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Seonyoung, Kim, Ah-Young, Cho, Hyeonseok, Baik, Deborah, Lee, Hankil, Cho, Sunghwa, Kang, Hye-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690091/
https://www.ncbi.nlm.nih.gov/pubmed/33243162
http://dx.doi.org/10.1186/s12885-020-07629-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690091/
https://www.ncbi.nlm.nih.gov/pubmed/33243162
http://dx.doi.org/10.1186/s12885-020-07629-z

Ejemplares similares